China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
05/26/05	$2.230	+1.36%	46,892
03/26/03	$2.200	-0.90%	49,728
02/26/02	$2.220	-9.76%	1,06,509
01/26/01	$2.460	-3.91%	1,29,887
31/26/31	$2.560	-14.67%	1,66,745

Delayed Quote Nasdaq

More quotes

Market Closed - Nasdaq 01:30:00 05/09/2026 am IST			5-day change	1st Jan Change
2.230 ^USD	+1.36%		-35.55%	-99.99%

05/08	Top Premarket Decliners	MT
30/07	Top Premarket Gainers	MT

Market Cap	10.51L 9L 9L 8L 14.54L 9.92Cr 14.58L 1.01Cr 39.02L 5.09Cr 39.47L 38.61L 16Cr	P/E 2025 *	-	P/E 2026	-
Enterprise Value	-2.61Cr -2.25Cr -2.12Cr -1.93Cr -3.62Cr -246.89Cr -3.63Cr -25Cr -9.71Cr -126.67Cr -9.82Cr -9.6Cr -408.07Cr	EV / Sales 2025	9.8x	EV / Sales 2026	-22.6x
Free-Float	66.63%	Yield 2025 *	-	Yield 2026	-

Markets		Quality
Nasdaq	SXTC	Delayed
CBOE	SXTC	Real-time
Deutsche Boerse AG	2RY2	Delayed
Tradegate	2RY2	Real-time

05/08	Top Premarket Decliners	MT
30/07	Top Premarket Gainers	MT
28/07	Top Premarket Decliners	MT
24/07	Top Premarket Decliners	MT
23/07	Top Premarket Decliners	MT
22/07	Top Premarket Gainers	MT
03/07	China SXT Pharmaceuticals, Inc. announced that it expects to receive $28.56 million in funding	CI
02/07	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
09/01	Top Midday Gainers	MT
01/01	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2025	CI
31/25/31	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2025	CI
28/25/28	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2024	CI
17/25/17	China Sxt Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Requirement	MT

China SXT Pharmaceuticals, Inc. Share Price

Stocks

SXTC

VGG2161P1734

Pharmaceuticals

Valuation : China SXT Pharmaceuticals, Inc.

Chart: China SXT Pharmaceuticals, Inc.

Latest news : China SXT Pharmaceuticals, Inc.

Analysts' recommendations : China SXT Pharmaceuticals, Inc.

Press Releases : China SXT Pharmaceuticals, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : China SXT Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

05/08	China SXT Pharmaceuticals, Inc. Announces Share Consolidation	AQ
25/07	Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)	AQ
23/07	China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering	AQ
02/07	China SXT Pharmaceuticals : Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)	PU
24/03	China SXT Pharmaceuticals, Inc. Announces Share Re-classification	AQ

1 day	+1.36%
1 week	-35.55%
Current month	-12.89%
1 month	-63.75%
3 months	-98.39%
6 months	-98.65%
Current year	-99.99%

1 week	2.06	3.05
1 month	2.06	6.31
Current year	2.06	83,758.33
1 year	2.06	83,758.33
3 years	2.06	6,13,438.04
5 years	2.06	6,73,07,692.31
10 years	2.06	4,49,03,84,615.38

Manager	Title	Age	Since
Sze Beng Lim CEO	Chief Executive Officer	-	20/01/2025
Feng Zhou CEO	Chief Executive Officer	34	04/07/2017
Xiaodong Pan DFI	Director of Finance/CFO	49	31/01/2022

Director	Title	Age	Since
Feng Zhou CHM	Chairman	34	04/07/2017
Jun Zheng BRD	Director/Board Member	49	31/12/2018
Xiaodong Ji BRD	Director/Board Member	57	22/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHINA SXT PHARMACEUTICALS, INC.	+1.36%	-35.55%	-99.99%	-100.00%	10.51L
ELI LILLY AND COMPANY	-0.88%	-2.27%	+55.78%	+106.31%	1,03400Cr
JOHNSON & JOHNSON	-1.15%	+3.56%	+54.62%	+71.50%	67TCr
ABBVIE INC.	-1.44%	-0.65%	+21.05%	+73.05%	46TCr
ROCHE HOLDING AG	+0.14%	-1.92%	+32.47%	+37.60%	35TCr
NOVARTIS AG	-1.33%	+3.96%	+25.71%	+45.03%	31TCr
ASTRAZENECA PLC	-1.15%	-0.89%	-1.67%	+12.21%	26TCr
AMGEN INC.	-1.55%	+0.05%	+54.04%	+70.32%	24TCr
NOVO NORDISK A/S	-0.88%	+1.24%	-18.03%	-54.06%	21TCr
GILEAD SCIENCES, INC.	-0.15%	+1.43%	+33.64%	+96.99%	19TCr
Average	-0.62%	-2.50%	+15.76%	+35.89%	37.17TCr
Weighted average by Cap.	-0.89%	+1.04%	+37.27%	+66.08%

	2025	2026
Net sales	17.41L 14.98L 14.09L 12.88L 24.09L 16Cr 24.15L 1.67Cr 64.63L 8.43Cr 65.37L 63.95L 27Cr	11.38L 10L 9L 8L 15.75L 11Cr 15.79L 1.09Cr 42.25L 5.51Cr 42.73L 41.8L 18Cr
Net income	-33.04L -28.43L -26.75L -24.43L -45.71L -31Cr -45.83L -3.16Cr -1.23Cr -16Cr -1.24Cr -1.21Cr -52Cr	-62.05L -53.39L -50.24L -45.89L -85.85L -59Cr -86.08L -5.94Cr -2.3Cr -30Cr -2.33Cr -2.28Cr -97Cr
Net Debt	-1.73Cr -1.48Cr -1.4Cr -1.28Cr -2.39Cr -162.9Cr -2.39Cr -17Cr -6.4Cr -84Cr -6.48Cr -6.34Cr -269.24Cr	-2.72Cr -2.34Cr -2.2Cr -2.01Cr -3.76Cr -256.81Cr -3.77Cr -26Cr -10Cr -131.76Cr -10Cr -9.99Cr -424.47Cr